FDA to promote development of coronavirus diagnostics and countermeasures
The US FDA has revealed its action plan to aid in the development and advancement of diagnostics and medical countermeasures to combat the novel coronavirus 2019.
List view / Grid view
News
Class 2 medicines recall of LEO Laboratories Picato gels
LEO Laboratories is recalling its Picato (ingenol mebutate) gels from pharmacies and wholesalers over a possible risk of skin malignancies; the products must be returned to suppliers for credit.
EC approves ustekinumab to treat plaque psoriasis in patients age six to 11
The European Commission has granted marketing authorisation to Stelara (ustekinumab) to treat patients aged six to 11 with moderate to severe plaque psoriasis.
Rise in pharmaceutical applications to increase demand for mass spectrometers in Europe
Researchers predict that the market for mass spectrometers will be worth $1.9 billion by 2025 due to demand for faster and more accurate technology.
Two awards granted to recognise work in bioprocessing industry
The UK BioIndustry Association’s bioProcessUK conference saw two awards given to Sharon Grimster and Dr Sarah Goulding for their work in the bioprocessing sector.
CEPI announces three programmes to develop coronavirus vaccine
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.
Boris Johnson announces UK Global Talent visa for researchers
Boris Johnson, the Prime Minister of the UK, has announced a new Global Talent visa for researchers and scientists which will fast track those in certain fields.
AstraZeneca announces plan for zero carbon emissions by 2025
AstraZeneca’s new carbon emission plan includes a 100 percent electric vehicle fleet and a 50 million tree reforestation plan.
FDA approves Tepezza for the treatment of thyroid eye in adults
The US FDA approved Tepezza (teprotumumab-trbw), the first treatment for thyroid eye, on the basis of two trials in which the drug improved eye protrusion in patients.
Tiofarma admits role in illegal agreement causing fludrocortisone price hikes
The CMA has announced Tiofarma admits taking part in an anti-competitive agreement with Amilco and Aspen which resulted in huge price increase in fludrocortisone acetate tablets.
NRDL list could lead to increased access to innovative drugs in China
China has started to regularly update its National Reimbursement Drug List (NRDL) which could lead to new opportunities for innovative drug manufacturers to foray into the Chinese market, say researchers.
Investigational New Drug application approved for LINCL treatment
The FDA has granted Investigational New Drug application to PLX-200 to treat late infantile neuronal ceroid lipofuscinosis (LINCL).
UK biotech records third highest year for investment, study finds
Research has revealed that the biotechnology industry was worth £1.3 billion in 2019, marking its third-highest year for investment.
Effectiveness of HPV vaccines Cervarix and Gardasil under question
Analysis of the designs of Phase II and III efficacy trials for HPV vaccines suggest they overstated their effectiveness against cervical cancer, according to researchers.
European Commission approves Sunosi® (solriamfetol)
EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
